Topics in Organic Chemistry: Modern Medicinal Chemistry (CHEM 515)
Fall 2005

Prof. W. P. Malachowski
Office: 270 Park
Phone: Ext. 5016
e-mail: wmalacho@brynmawr.edu
web page: http://www.brynmawr.edu/chemistry/malachowski
course web page: located on blackboard

Prof. S. A. White
Office: 202 Park
Phone: Ext. 5107
e-mail: swhite@brynmawr.edu
web page: http://www.brynmawr.edu/chemistry/swhite.html

Class meetings:  Tues. and Thurs. 10:00-11:30 AM.  All class meetings will be held in PSB 278 unless otherwise noted.

Office Hours:  W. Malachowski: Mon. 9:30-10:30 AM, Wed. 4-5:30 PM and by appointment.  S. White: Tues. 2-4 PM, Thurs. 11:30-12:30 PM.                      

Suggested Reference Books (on reserve at Collier Science Library):
General Medicinal Chemistry Topics:
The Organic Chemistry of Drug Design and Drug Action, 1992, by Richard B. Silverman
An Introduction to Medicinal Chemistry: How Drugs Act and Why, 1997, Alex Gringauz
Rational Drug Design:
The Organic Chemistry of Enzyme-catalyzed Reactions, 2002, by Richard B. Silverman
Design of Enzyme Inhibitors as Drugs, 1989, edited by Merton Sandler and H. John Smith 
Drug/Generic Name, Mode of Action, Chemical Structure Information:
The Merck Index
Physician’s Desk Reference
Goodman and Gilman’s The Pharmacological Basis of Therapeutics

Tentative Schedule

Date (Lecture No.)

Topic

Instructor

Aug. 30 (1)

Introduction/Lead Discovery

Malachowski/White

Sept. 1 (2)

Lead Development

Malachowski

Sept. 6 (3)

Lead Development

Malachowski

Sept. 8 (4)

Molecular Biology and Lead Development: x-ray crystallography, understanding drug resistance and related topics

 

White

Sept. 13 (5)

Quantitative Structure-Activity Relationships (QSAR)

Malachowski

Sept. 15 (6)

Development of an H2 histamine antagonist for ulcer treatment: Cimetidine (Tagamet)


Malachowski

Sept. 20 (7)

Development of an H2 histamine antagonist for ulcer treatment: Cimetidine (Tagamet)

Malachowski

Sept. 22 (8)

Pharmacokinetics/Drug Metabolism

Malachowski

Sept. 27 (9)

Drug Metabolism

Malachowski

Sept. 29 (10)

Development of an ACE inhibitor therapy for hypertension treatment: Captopril (Capoten) and Enalapril (Vasotec)


Malachowski

Oct. 4 (11)

Development of an ACE inhibitor therapy for hypertension treatment: Captopril (Capoten) and Enalapril (Vasotec)


Malachowski

Oct. 6 (12)

AIDS treatments: A survey of targets in HIV
*Select a literature article for paper

 

White

Oct. 8-16

Fall Break

 

Oct. 18 (12)

AIDS treatments: A survey of targets in HIV

White

Oct. 20 (13)

Develpment of HIV protease inhibitor therapy for AIDS

Malachowski

Oct. 25 (14)

Develpment of HIV protease inhibitor therapy for AIDS
 *Papers due today


Malachowski

Oct. 27 (15)

Tumor angiogenesis treatment by regulation of gene expression with small, DNA sequence-specific binding molecules

 

White

Nov. 1 (16)

Tumor angiogenesis treatment by regulation of gene expression with small, DNA sequence-specific binding molecules

*Mid-term exam distributed today

 

 

White

Nov. 3 (17)

Tuberculosis Treatment

Malachowski

Nov. 8 (18)

Tuberculosis Treatment

Malachowski

Nov. 10 (19)

Parasitic Diseases: River Blindness

White

Nov. 15 (20)

Malaria

White

Nov. 17 (21)

Analgesics: Aspirin and COX-2 inhibitors

Mary Kim/Stephanie Sarandon

Nov. 22

Schizophrenia treatment: Chlorpromazine and ziprasidone

Ronke Imbeah-Ampiah/Hina Omar

Nov. 24

Thanksgiving Break

 

Nov. 29 (22)

Anti-coagulant treatments: Warfarin and heparin

Sruti Bhaumik/Darae Ko

Dec. 1 (23)

Anti-depression treatment: Prozac

Shadia Bel Hamdounia/Elizabeth Keller/Dustin Raup

Dec. 6 (24)

Insomnia treatments: melatonin receptor agonists

Jisun Lee/Andrew Harron

Dec. 8 (25)

Alzheimer’s Disease: beta-secretase inhibitors

Marisha Banerji/Anna Merkle

Exams:  One mid-semester take-home exam will be distributed on approximately Nov. 1.

Papers:  Students will select an article involving drug development from the scientific literature by Oct. 4 and write a summary (3-5 pages) of the article by Oct. 25.

Student-lead discussions:  Students will select an article involving drug development, provide a brief summary of the research and lead a discussion of the work in class.

Final Exam: There will be a take-home final exam distributed at the last class meeting.

Course Grading:

    Exam:                                 100 pts.
    Paper:                                 100 pts.
    Presentation:                       100 pts.
    Final Exam: 150 pts. (x 1)=150 pts.
                     Total Points:      450 pts.

    Approximate Grading Scheme:    93-100%     4.0    73-76%       2.0
                                                           89-92%      3.7     70-72%      1.7
                                                           86-88%      3.3     67-69%      1.3
                                                           82-85%      3.0     63-66%      1.0
                                                           80-82%      2.7     <63%         0.0
                                                           77-79%      2.3
We reserve the right to make modifications to this scheme when I consider it necessary.

Students with Disabilities: Students who think they may need accommodations in this course because of the impact of a disability are encouraged to meet with me privately early in the semester. Students should also contact Stephanie Bell, Coordinator of Access Services, at 610-526-7351 or sbell@brynmawr.edu, as soon as possible to verify their eligibility for reasonable accommodations. Early contact will help to avoid unnecessary inconvenience and delays.